E-cadherin在胰腺癌中的表达及其对预后的影响

Relationship between the Expression of E-cadherin and Clinic-pathologic Characteristics and Prognosis in Pancreatic Ductal Adenocarcinoma

目的:探讨钙粘蛋白E-cadherin的表达与胰腺导管腺癌临床病理特征及预后的关系。方法:利用组织芯片,采用免疫组织化学En Vision二步法检测106例胰腺导管腺癌组织和12例正常胰腺组织E-cadherin的表达情况。结果:E-cadherin在胰腺导管腺癌组织中表达部分缺失率为53.8%(57/106),完全缺失率11.3%(12/106),正常组织中的缺失率为0%,差异有统计学意义(P<0.01);E-cadherin的表达与患者性别、年龄,临床分期、神经浸润和淋巴结转移无关,与肿瘤分化程度有关。106例胰腺导管腺癌患者E-cadherin表达完全缺失、部分缺失和完整表达的中位总生存期分别为7个月、19个月和25个月,两者差异有统计学意义(P<0.01)。单因素分析显示,肿瘤分化程度、淋巴结转移、切缘情况和E-cadherin表达缺失水平与预后相关;多因素分析显示,切缘情况和E-cadherin表达缺失水平与预后相关。结论:E-cadherin可以作为胰腺导管腺癌患者预后的独立指标。

Objective： To explore the relationship between the expression of E-cadherin and its clinic-pathologic characteristics and prognosis in pancreatic ductal adenocarcinoma （PDAC）. Methods： The expression of E-cadherin in 106 cases of PDAC tissues and 12 cases of normal pancreatic tissues were examined by En Vision method. Results： The ＇partial loss＇ rate of E-cadherin was 53.8% （57/106） and ＇total loss＇ rate was 11.3%（12/106） in PDAC tissues. The loss rate of E-cadherin was 0% in normal tissues, the difference was statistically significant （P〈0.01）. The expression of E-cadherin protein were not correlated with gender, age, clinical stage, lymph node metastasis and perineural invasion, but correlated with differentiation. The median overall survival of of E-cadherin ＇total loss＇ ex- pression cases was 7 months, lower than 19 months in ＇partial loss＇ expression ceases and 25 months in ＇intact＇ expression eases （P〈0.01）. Univariate analysis showed differentiation, lymph node metastasis, resection margin and E-cadherin expression influenced the survival of PDAC patients. While multivariate analysis showed E-cadherin expression and resection margin were the only factors related to the prog- nosis of PDAC patients （P〈0.01）. Conclusion： E-cadherin may be used as a molecular marker to identify and predict the prognosis of PDAC.